Ovarian Cancer Population Screening and Mortality After Long-Term Follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomised Controlled Trial. Issue 9 (September 2021)

• Record Type: Journal Article
• Authors: Menon, Usha; Gentry-Maharaj, Aleksandra; Burnell, Matthew; Singh, Naveena; Ryan, Andy; Karpinskyj, Chloe; Carlino, Giulia; Taylor, Julie; Massingham, Susan K.; Raikou, Maria; Kalsi, Jatinderpal K.; Woolas, Robert; Manchanda, Ranjit; Arora, Rupali; Casey, Laura; Dawnay, Anne; Dobbs, Stephen; Leeson, Simon; Mould, Tim; Seif, Mourad W.; Sharma, Aarti; Williamson, Karin; Liu, Yiling; Fallowfield, Lesley; McGuire, Alistair J.; Campbell, Stuart; Skates, Steven J.; Jacobs, Ian J.; Parmar, Mahesh
• Is Part Of: Obstetrical & gynecological survey. Volume 76:Issue 9(2021)
• Publication Date: 2021-09
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/01.ogx.0000792624.55995.3e
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from Lancet 2021;397:2182–2193) Ovarian cancer is most commonly diagnosed at an advanced stage (3 or 4) and remains the deadliest gynecologic malignancy. When diagnosed at stage 1, a survival rate of greater than 90% has been demonstrated, compared with a 5-year survival rate of 27% and 13% for stage 3 and stage 4 disease, respectively.